These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 14619970)

  • 21. Possibilities and challenges for developing a successful vaccine for leishmaniasis.
    Srivastava S; Shankar P; Mishra J; Singh S
    Parasit Vectors; 2016 May; 9(1):277. PubMed ID: 27175732
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunology of leishmaniasis.
    Liew FY; O'Donnell CA
    Adv Parasitol; 1993; 32():161-259. PubMed ID: 8237615
    [No Abstract]   [Full Text] [Related]  

  • 23. Modes of action of Leishmanicidal antimicrobial peptides.
    Marr AK; McGwire BS; McMaster WR
    Future Microbiol; 2012 Sep; 7(9):1047-59. PubMed ID: 22953706
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New approaches from nanomedicine for treating leishmaniasis.
    Gutiérrez V; Seabra AB; Reguera RM; Khandare J; Calderón M
    Chem Soc Rev; 2016 Jan; 45(1):152-68. PubMed ID: 26487097
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of leishmaniasis: a review and assessment of recent research.
    Elmahallawy EK; Agil A
    Curr Pharm Des; 2015; 21(17):2259-75. PubMed ID: 25543123
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent patents in the treatment and prevention of leishmaniasis.
    Shahid SK
    Pharm Pat Anal; 2023 Sep; 12(5):237-248. PubMed ID: 38063376
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Leishmaniasis and various immunotherapeutic approaches.
    Taslimi Y; Zahedifard F; Rafati S
    Parasitology; 2018 Apr; 145(4):497-507. PubMed ID: 27974063
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent updates and perspectives on approaches for the development of vaccines against visceral leishmaniasis.
    Duarte MC; Lage DP; Martins VT; Chávez-Fumagalli MA; Roatt BM; Menezes-Souza D; Goulart LR; Soto M; Tavares CA; Coelho EA
    Rev Soc Bras Med Trop; 2016; 49(4):398-407. PubMed ID: 27598624
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Leishmaniasis.
    Evans TG
    Infect Dis Clin North Am; 1993 Sep; 7(3):527-46. PubMed ID: 8254158
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Leishmaniasis in humans: drug or vaccine therapy?
    Ghorbani M; Farhoudi R
    Drug Des Devel Ther; 2018; 12():25-40. PubMed ID: 29317800
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antileishmanial Drug Discovery: Synthetic Methods, Chemical Characteristics, and Biological Potential of Quinazolines and its Derivatives.
    Sahu A; Kumar D; Agrawal RK
    Antiinflamm Antiallergy Agents Med Chem; 2017; 16(1):3-32. PubMed ID: 28464778
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Parasite candidate vaccines: a warning from polymorphic Leishmania populations.
    Guerbouj S; Guizani I; Victoir K; Le Ray D; Dujardin JC
    Parasitol Today; 2000 Jun; 16(6):265. PubMed ID: 10827439
    [No Abstract]   [Full Text] [Related]  

  • 33. Vaccine candidates for leishmaniasis: a review.
    Nagill R; Kaur S
    Int Immunopharmacol; 2011 Oct; 11(10):1464-88. PubMed ID: 21616175
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapy in treatment of leishmaniasis.
    Akbari M; Oryan A; Hatam G
    Immunol Lett; 2021 May; 233():80-86. PubMed ID: 33771555
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multicomponent LBSap vaccine displays immunological and parasitological profiles similar to those of Leish-Tec® and Leishmune® vaccines against visceral leishmaniasis.
    de Mendonça LZ; Resende LA; Lanna MF; Aguiar-Soares RD; Roatt BM; Castro RA; Batista MA; Silveira-Lemos D; Gomes Jde A; Fujiwara RT; Rezende SA; Martins-Filho OA; Corrêa-Oliveira R; Dutra WO; Reis AB; Giunchetti RC
    Parasit Vectors; 2016 Aug; 9(1):472. PubMed ID: 27577735
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Leishmaniasis.
    Herwaldt BL
    Lancet; 1999 Oct; 354(9185):1191-9. PubMed ID: 10513726
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current status and perspectives of the immunotherapy of leishmaniasis.
    El-On J
    Isr Med Assoc J; 2009 Oct; 11(10):623-8. PubMed ID: 20077951
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dendritic Cells and Leishmania Infection: Adding Layers of Complexity to a Complex Disease.
    Feijó D; Tibúrcio R; Ampuero M; Brodskyn C; Tavares N
    J Immunol Res; 2016; 2016():3967436. PubMed ID: 26904694
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drugs against leishmaniasis: a synergy of technology and partnerships.
    Davis AJ; Murray HW; Handman E
    Trends Parasitol; 2004 Feb; 20(2):73-6. PubMed ID: 14747020
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antimicrobial peptides for leishmaniasis.
    Cobb SL; Denny PW
    Curr Opin Investig Drugs; 2010 Aug; 11(8):868-75. PubMed ID: 20721829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.